Nasus Pharma (NSRX) CFO discloses 126,197 unvested options at $7.56 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nasus Pharma Ltd executive Rubin Eyal, the Chief Financial Officer and EVP, filed an initial ownership report showing he holds unvested share options over 85,648 and 40,549 ordinary shares. These options, all at an exercise price of $7.56 per share, were granted on November 20, 2025 and expire on November 20, 2035.

As of March 18, 2026, all 126,197 options remain outstanding and unvested under time-based vesting schedules, and the filing does not report any share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rubin Eyal

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Share options (right to buy)	--	--	--
holding	Share options (right to buy)	--	--	--

Holdings After Transaction: Share options (right to buy) — 85,648 shares (Direct)

Footnotes (1)

Options to purchase 85,648 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 20, 2025 with 8.3333% of the total grant vesting 457 days following November 20, 2025, and the remaining 91.6667% vesting in equal quarterly installments of 8.3333% thereafter. As of March 18, 2026, 85,648 options remain outstanding, none of which are vested, at an exercise price of $7.56 per share, expiring November 20, 2035. Options to purchase 40,549 Ordinary Shares were granted on November 20, 2025, with 100% of the total grant vesting on November 20, 2026. As of March 18, 2026, 40,549 options remain outstanding, none of which are vested, at an exercise price of $7.56 per share, expiring November 20, 2035.

Understanding Insider Trading Forms →

03/27/2026 - 09:37 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rubin Eyal

(Last)

(First)

(Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO

6100201

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Financial Officer		EVP

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share options (right to buy)⁽¹⁾	02/27/2027	11/20/2035	Ordinary Shares	85,648	$7.56	D
Share options (right to buy)⁽²⁾	11/20/2026	11/20/2035	Ordinary Shares	40,549	$7.56	D

Explanation of Responses:

1. Options to purchase 85,648 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 20, 2025 with 8.3333% of the total grant vesting 457 days following November 20, 2025, and the remaining 91.6667% vesting in equal quarterly installments of 8.3333% thereafter. As of March 18, 2026, 85,648 options remain outstanding, none of which are vested, at an exercise price of $7.56 per share, expiring November 20, 2035.

2. Options to purchase 40,549 Ordinary Shares were granted on November 20, 2025, with 100% of the total grant vesting on November 20, 2026. As of March 18, 2026, 40,549 options remain outstanding, none of which are vested, at an exercise price of $7.56 per share, expiring November 20, 2035.

	/s/ Eyal Rubin	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Nasus Pharma (NSRX) CFO Rubin Eyal report in this Form 3?

Nasus Pharma CFO Rubin Eyal reports initial ownership of two unvested option grants. They cover 85,648 and 40,549 ordinary shares at an exercise price of $7.56, all expiring on November 20, 2035, with no share purchases or sales disclosed.

How many Nasus Pharma (NSRX) shares are covered by Rubin Eyal’s options?

Rubin Eyal’s options cover a total of 126,197 ordinary shares of Nasus Pharma. This includes 85,648 options and 40,549 options, all granted on November 20, 2025, according to the Form 3 initial ownership filing.

What are the vesting terms of Rubin Eyal’s Nasus Pharma (NSRX) options?

One grant of 85,648 options vests 8.3333% after 457 days from November 20, 2025, with the remaining 91.6667% vesting in equal quarterly installments. The separate 40,549-option grant vests 100% on November 20, 2026, if service-based conditions are met.

Are Rubin Eyal’s Nasus Pharma (NSRX) options vested as of March 18, 2026?

As of March 18, 2026, none of Rubin Eyal’s options are vested. The filing states all 85,648 and 40,549 options remain outstanding and unvested, subject to their respective vesting schedules and the $7.56 per share exercise price.

What is the exercise price and expiration of Nasus Pharma (NSRX) options held by Rubin Eyal?

All reported options have an exercise price of $7.56 per ordinary share and expire on November 20, 2035. These terms apply to both the 85,648-option grant and the 40,549-option grant disclosed in the Form 3 filing.